The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV
Authors: David A Cooper, Alex D Wodak and Brian J Morris
Published online: 20 September 2010
Circumcision now to prevent heterosexual HIV transmission in 2030 makes sense
Australia is rightly proud of its response to HIV. Thanks to superb formulation of public policy in the early days of the epidemic, it is not only a low-prevalence country but an international leader in many aspects of its clinical and public health responses. To maintain this fine record, Australia should change policy so that infant male circumcision rates are boosted in the face of rising heterosexual transmission of HIV.
Regular surveillance indicates that HIV in Australia is slowly following the trend in Western Europe and North America toward an increased proportion of transmission occurring through heterosexual contact.1 Although the epidemic in Australia is likely to remain concentrated for some time among men who have sex with men, the proportion of new diagnoses attributable to heterosexual contact has risen from the negligible levels of the epidemic’s early days.1
The World Health Organization, the Joint United Nations Programme on HIV/AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria have endorsed male circumcision to control HIV attributed to heterosexual contact in hyperendemic areas, stating: “The efficacy of male circumcision in reducing female to male transmission of HIV has been proven beyond reasonable doubt. This is an important landmark in the history of HIV prevention.”2
This raises the question of whether low-prevalence countries such as Australia — with an increasing proportion of HIV cases attributed to heterosexual contact — should consider increasing the rate of infant male circumcision to reduce future HIV infections. The protection conferred to heterosexual males by circumcision is similar in hyperendemic and low-prevalence settings.3-5 In 2008, the Centers for Disease Control and Prevention (CDC) concluded that male circumcision “may also have a role in the prevention of HIV transmission in the United States”.3 The CDC is now formulating a new policy.4
Being a low-prevalence country does not preclude a population-wide approach to HIV prevention. For example, we test pregnant women to prevent cases of vertical HIV transmission. Infant male circumcision would be a comparable, albeit more interventionist, population-wide strategy.
A wealth of research has shown that the foreskin is the entry point that allows HIV to infect men during intercourse with an infected female partner.5,6 Soon after the HIV pandemic was first recognised, much lower HIV prevalence was found in areas of sub-Saharan Africa where more than 80% of males had been circumcised than in areas where the circumcision rate was less than 20%.5,6 These findings were then replicated in Asia.7 In Australia, infant male circumcision was once routine, but plummeted in the 1970s.
Circumcision of males is now referred to by many as a “surgical vaccine” against a wide variety of infections and adverse medical conditions over the lifetime.5,6,8,9 The public health benefits include protection not just from sexually transmitted HIV, but also from some common sexually transmitted infections and other conditions.4-6 Although it can be performed at any age, the ideal time is infancy, when adverse effects are uncommon.4-6 Considerable evidence, including data from randomised controlled trials, shows that male circumcision has no adverse effects on sexual function, sensitivity or satisfaction.4-6,8
At present, the major obstacle to increasing the rates of infant male circumcision in Australia is an influential Royal Australasian College of Physicians policy, which has been criticised on scientific grounds.10 A draft of a new policy has also been criticised in a detailed petition by 38 academic and clinical experts (including Fellows of the College). Another barrier is the Medicare rebate, which has been reduced steadily in real terms over many years. No state or territory Department of Health except Queensland Health allows elective infant male circumcision to be performed in public hospitals.
Despite official discouragement, Medicare statistics show a rise in the rate of infant male circumcision in Australia from 13% in 1998 to 19% in 2009. Boosting the rate in Australia, as a long-term strategy to reduce HIV transmission (in combination with other interventions), is sound public health policy. Male circumcision is one of the most powerful interventions that is currently available in the fight against HIV.8,9 The prospect of the availability of a vaccine over the next 20 years is unlikely. Thus, circumcision now to prevent heterosexual HIV transmission in 2030 makes sense.
In addition to preventing HIV transmission, other benefits, high cost-effectiveness11 and risk–benefit balance5,10,11 justify acceptance of male circumcision as a sensible public health measure.3,5,6 It should be viewed as part of a safer sex package. Condom use remains essential, with promotion of condom use plus circumcision of males being analogous to seatbelts plus airbags for reducing the road toll.
Australia would also be acting compassionately if it promoted infant male circumcision in the Asia–Pacific region, especially in Papua New Guinea where a generalised HIV epidemic has become well established. A commitment to increasing infant male circumcision should complement earlier commitments to other strategies for prevention of sexually transmitted infections, including condom use.
Twenty-nine years after the existence of this epidemic was first announced, it is clear that a new chapter has opened with the recognition that male circumcision substantially reduces female-to-male HIV transmission. Australia would be wise to take advantage of this knowledge.
References
- National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2009. http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/resources/SurvReports_3/$file/ASR2009-updated-2.pdf (accessed Aug 2010).
- World Health Organization, UNAIDS. New data on male circumcision and HIV prevention: policy and programme implications. 28 Mar 2007. http://www.who.int/hiv/mediacentre/MCrecommendations_en.pdf (accessed Aug 2010).
- Centers for Disease Control and Prevention. Male circumcision and risk for HIV transmission and other health conditions: implications for the United States [CDC HIV/AIDS science facts]. Atlanta: CDC, 2008. http://www.cdc.gov/hiv/resources/factsheets/circumcision.htm (accessed Aug 2010).
- Smith DK, Taylor A, Kilmarx PH, et al. Male circumcision in the United States for the prevention of HIV infection and other adverse health outcomes: report from a CDC consultation. Public Health Rep 2010; 125 Suppl 1: 72-82. i1095507
- Morris BJ. Why circumcision is a biomedical imperative for the 21st century. Bioessays 2007; 29: 1147-1158. i1095509
- Tobian AA, Gray RH, Quinn TC. Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med 2010; 164: 78-84. i1095511
- Reynolds SJ, Shepherd ME, Risbud AR, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004; 363: 1039-1040. i1095513
- Wamai RG, Weiss HA, Hankins C, et al. Male circumcision is an efficacious, lasting and cost-effective strategy for combating HIV in high-prevalence AIDS epidemics [letter]. Future HIV Ther 2008; 2: 399-405. i1095515
- Klausner JD, Wamai RG, Bowa K, et al. Is male circumcision as good as the HIV vaccine we’ve been waiting for [editorial]? Future HIV Ther 2008; 2: 1-7. i1095517
- Morris BJ, Bailis SA, Castellsague X, et al. RACP’s policy statement on infant male circumcision is ill-conceived. Aust N Z J Public Health 2006; 30: 16-22. i1095519
- Schoen EJ, Colby CJ, To TT. Cost analysis of neonatal circumcision in a large health maintenance organization. J Urol 2006; 175: 1111-1115. i1095522
Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study
Andrew Palmer, Matthew Carter, Jeremy Yeo, Cecilia Shim, Jason Connor, Jeremy Hayllar, Gerald Holtmann, Naomi Moy, Elliott G. Playford, Naomi Runnegar, Paul J. Clark
The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention
Cyra Patel, Alexis Pillsbury, Tran Nguyen, Xia Wang, Helen E. Quinn, Clayton K. Chiu, Allen C. Cheng, Katie L. Flanagan, Zhicheng Wang
Reflex Testing for Hepatitis D Infection: A Unique Opportunity to Reduce Hepatitis D-Related Chronic Liver Disease Deaths in Australia
Jessica Howell, Lauren Andersson, Miriam T. Levy, James O'Beirne, Leon Adams, Katharine Irvine, Avik Majumdar, Golo Ahlenstiel, Kathy Jackson, Krispin Hajkowicz, Joseph Doyle, Jane Davies, Sarah Cherian, Wayne Dimech, Alexander J. Thompson
Localised Herpes Simplex Following Midline Laparotomy
Jessica S. Bulluss, Paul Chee, Matthew J. Verheyden
West Nile virus Kunjin subtype in rural NSW
Emily Gibson, Megan Whitley, Peter Murray, Linda Hueston, Jane Bennett, Raguharan Kathiresu, David N Durrheim
Differentiated and simplified oral HIV pre‐exposure prophylaxis (PrEP) models hold the key to virtually eliminating HIV transmission in Australia by 2030
Tyson Arapali, Sarah Warzywoda, Anthony K J Smith, Curtis Chan, Timothy R Broady, Erin Sullivan, Catherine MacPhail, Mohamed A Hammoud, Alexander Dowell‐Day, Benjamin R Bavinton